NCT06313996 2026-03-18
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 3 Withdrawn
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Fate Therapeutics
ADC Therapeutics S.A.
SecuraBio
Bristol-Myers Squibb
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
GlaxoSmithKline
Janssen Pharmaceutica